Benzinga | Aug 6, 2020 04:12PM EDT

Acceleron Pharma Q2 EPS $(0.34) Beats $(0.57) Estimate, Sales $39.75M Beat $30.08M Estimate

Acceleron Pharma (NASDAQ:XLRN) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.57) by 40.35 percent. This is unchanged from the same period last year. The company reported quarterly sales of $39.75 million which beat the analyst consensus estimate of $30.08 million by 32.15 percent. This is a 43.69 percent increase over sales of $27.67 million the same period last year.